Highlights and Quick Summary
- SG&A Expenses for the quarter ending October 31, 2022 was $2.15 Million (a 58.26% increase compared to previous quarter)
- Year-over-year quarterly SG&A Expenses decreased by -2.31%
- Annual SG&A Expenses for 2022 was $7.27 Million (a 46.67% increase from previous year)
- Annual SG&A Expenses for 2021 was $4.96 Million (a 227.37% increase from previous year)
- Annual SG&A Expenses for 2020 was $1.51 Million (a 53.54% increase from previous year)
- Twelve month SG&A Expenses ending October 31, 2022 was $8.01 Million (a 10.16% increase compared to previous quarter)
- Twelve month trailing SG&A Expenses decreased by -11.22% year-over-year
Trailing SG&A Expenses for the last four month:
31 Oct '22 | 31 Jul '22 | 30 Apr '22 | 31 Jan '22 |
---|---|---|---|
$8.01 Million | $7.27 Million | $6.93 Million | $9.02 Million |
Visit stockrow.com/BCTX
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical SG&A Expenses of BRIACELL THERAP
Most recent SG&A Expensesof BCTX including historical data for past 10 years.Interactive Chart of SG&A Expenses of BRIACELL THERAP
BRIACELL THERAP SG&A Expenses for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
---|---|---|---|---|---|
2022 | $2.15 | $1.36 | $2.3 | $2.2 | $7.27 |
2021 | $1.41 | $1.02 | $4.39 | $0.02 | $4.96 |
2020 | $0.23 | $0.29 | $0.3 | $0.5 | $1.51 |
2019 | $0.42 | $0.28 | $0.3 | $0.18 | $0.99 |
2018 | $0.22 | $0.54 | $0.59 | $0.19 | $1.46 |
2017 | $0.14 | $0.22 | $0.3 | $0.17 | $0.82 |
2016 | $0.13 | $-0.13 | $0.24 | $0.64 | $0.93 |
2015 | $0.16 | $0.11 | $0.35 | $2.0 | $2.5 |
2014 | $0.06 | $0.17 | $0.1 | $0.09 | $0.44 |
2013 | $0.08 | $0.1 | $0.12 | $0.11 | $0.43 |
2012 | $0.11 | $0.15 | $0.11 | $0.14 | $0.55 |
Business Profile of BRIACELL THERAP
Sector: Healthcare
Industry: Biotechnology